Although the role of radiation therapy is well established in this setting, the role of radical prostatectomy in treating men with de novo oligometastatic prostate cancer has not been well defined.

There is a high unmet need for effective neoadjuvant treatments for muscle-invasive bladder cancer for patients who cannot tolerate or refuse cisplatin chemotherapy.

Investigators identify causative pathogens and risk factors for post-cystectomy UTI and associations with survival.

Active surveillance may be an appropriate option for older patients and those with greater comorbidity burden and worse ...

Despite its complexity, partial nephrectomy still provides the best survival rates among treatment options in patients aged 75 years or older with T1-T2 renal cell carcinoma (RCC). Investigators ...

More than 2 decades have passed since I became the first full-time editor of Renal & Urology News. During that time, the ...

The FDA expanded the approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and are considered appropriate to ...

The FDA has approved Imfinzi® (durvalumab), in combination with gemcitabine and cisplatin, for the treatment of adult patients with MIBC.

Discrepancies between clinical and pathologic staging of muscle-invasive bladder cancer (MIBC) are found in three-quarters of ...

A trial tested MRI and microultrasonography guided biopsy separately and in combination for the detection of clinically significant prostate cancer.

Immune checkpoint inhibitors have shown a survival benefit in patients with metastatic urothelial cancer, so investigators trialed neoadjuvant nivolumab and ipilimumab in patients with muscle-invasive ...

Higher weighted years with overweight/obesity linked to increased risk for overall, aggressive, fatal, and clear-cell renal cell carcinoma ...